Publication date: Jun 12, 2025
Objectives: This study aims to describe the experience of using ECMO on various patients who require ECMO support during the entire perioperative period of lung transplantation. ECMO has several roles: it can bridge patients to transplantation, improve lung graft function in case of primary graft dysfunction after transplantation, improve left ventricle function after transplantation in patients with primary pulmonary hypertension, and manage COVID-19 patients who are awaiting LuTx or undergoing LTx. Methods: We present 6-year results from a high-volume lung transplant center (219 cases/6 years, >50 cases/2022). We used ECMO in 56 cases (25. 6%) of all lung transplants between 2018 and 2023. Results: The one-year survival rate of patients transplanted on ECMO was 85. 7%. We applied all advanced ECMO techniques, such as bridging to transplantation on ECMO (n = 15, early survival 66. 7%) and left ventricular conditioning after LuTx with VA-ECMO (n = 12, 60-day and one-year survival 85. 1% and 53%, respectively). We also bridged patients with COVID-19 to transplantation and transplanted them from ECMO (n = 9, early survival 55%). Conclusions: This article shows possible applications of ECMO therapy for various indications in lung transplant patients and, along with data from other publications, it demonstrates that ECMO can improve survival and outcomes for patients with respiratory failure, primary pulmonary hypertension, and COVID-19. The COVID-19 pandemic highlighted new utilization of ECMO, demonstrating its usefulness and importance in critical care medicine. Further research into capabilities of the ECMO system may expand the knowledge about its role in lung transplantation and future treatments.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Hypertension | awake-ECMO |
| Medicine | COVID-19 transplantation |
| Transplantation | ECMO |
| ECMO-bridge | |
| left ventricular conditioning | |
| lung transplantation | |
| sport-ECMO |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | primary graft dysfunction |
| disease | MESH | primary pulmonary hypertension |
| disease | MESH | respiratory failure |
| disease | IDO | role |
| disease | MESH | Heart Diseases |
| disease | MESH | Interstitial Lung Diseases |
| disease | MESH | cardiac failure |
| disease | MESH | critically ill |
| disease | IDO | process |
| disease | IDO | site |
| disease | MESH | contraindications |
| disease | MESH | acute respiratory distress syndrome |
| drug | DRUGBANK | Aminohippuric acid |
| disease | MESH | hypertension |
| disease | MESH | pulmonary hypertension |
| disease | MESH | left ventricular dysfunction |
| disease | MESH | death |
| disease | MESH | complications |
| disease | MESH | stroke |
| disease | MESH | palsy |
| disease | MESH | bleeding |
| disease | MESH | ischemia |
| disease | MESH | infection |
| drug | DRUGBANK | Heparin |
| disease | MESH | pulmonary arterial hypertension |
| disease | MESH | pulmonary edema |